---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-090113"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2025-09-16T23:59:59+00:00"
generated_at: "2026-05-17T06:28:52.202459+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ocugen licenses OCU400 gene therapy to Kwangdong for South Korea; $1M upfront, up to $6.5M milestones

## Summary
- Exclusive license to Kwangdong for OCU400 (retinitis pigmentosa gene therapy) in South Korea.
- $1M upfront; up to $6.5M in regulatory/development milestones plus sales milestones of $1.5M per $15M sales.
- Royalty of 25% on net sales; Ocugen to manufacture commercial supply under separate agreement.
- Term continues until 20 years after first commercial sale or last valid patent/exclusivity expiry.

## SEC filing metadata
- accession: 0001104659-25-090113
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2025-09-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/0001104659-25-090113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000110465925090113/tm2526167d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-090113
- JSON: https://secwatch.observer/filing/0001104659-25-090113.json
- Plain text: https://secwatch.observer/filing/0001104659-25-090113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.